Background: There is a need to improve the safety and efficacy of allergen-specific
immunotherapy. Long synthetic peptide-based immunotherapy was proven safe,
immunogenic, and protective in preclinical trials. Objective: To evaluate the safety and
immunogenicity of an allergen-derived long synthetic overlapping peptide (LSP)
immunotherapy, we designed a double-blind, placebo-controlled phase I clinical trial in
patients hypersensitive to bee venom. Methods: Patients from the active group were injected …